Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

Jason S Gold ¹, Mithat Gönen , Antonio Gutiérrez

⁰Department of Surgery VA Boston Healthcare System/Brigham and Women's Hospital West Roxbury, MA, USA.

The Lancet. Oncology +

|

October 2, 2009

View abstract on PubMed

Summary

A new nomogram accurately predicts recurrence-free survival (RFS) in gastrointestinal stromal tumors (GIST) patients post-surgery. This tool aids in selecting patients who may benefit from adjuvant imatinib therapy.

Area Of Science

Oncology
Surgical Oncology
Pharmacology

Background

Adjuvant imatinib mesylate improves recurrence-free survival (RFS) for localized primary gastrointestinal stromal tumors (GIST) after surgical resection.
Accurate prediction of RFS is crucial for guiding patient selection for adjuvant imatinib therapy.
Existing staging systems may not fully capture individual RFS risk post-GIST resection.

Purpose Of The Study

To develop and validate a predictive nomogram for RFS in patients with localized primary GIST.
To assess the nomogram's performance against established staging systems for predicting RFS.
To provide a tool for optimizing patient selection for adjuvant imatinib therapy.

Main Methods

A nomogram was developed using data from 127 GIST patients at Memorial Sloan-Kettering Cancer Center (MSKCC).
Predictive factors included tumor size, location (stomach, small intestine, colon/rectum, other), and mitotic index.
The nomogram was validated in independent cohorts from the Spanish Group for Research on Sarcomas (GEIS; n=212) and the Mayo Clinic (n=148).

Main Results

The nomogram demonstrated strong predictive accuracy with concordance probabilities of 0.78 (MSKCC), 0.76 (GEIS), and 0.80 (Mayo).
Nomogram predictions showed good calibration, indicating reliable RFS estimations.
The nomogram outperformed two NIH staging systems and performed comparably to the AFIP-Miettinen system, with potentially better calibration.

Conclusions

The developed nomogram accurately predicts RFS after resection of localized primary GIST.
This validated nomogram can serve as a valuable tool for identifying patients who would benefit from adjuvant imatinib therapy.
The nomogram offers improved risk stratification compared to some existing staging systems.

Related Concept Videos